In the Hole

Harvard assesses the feasibility of completing capital projects now under way, and the timing of other parts of its institutional master plan.

For an update posted after this issue went to press, see "Faust: University Will Slow Pace of Construction in Allston."

Construction continued apace in early February on the foundations of Harvard’s first science complex in Allston, a roughly 1-million-square-foot, billion-dollar facility slated to house the Harvard Stem Cell Institute (HSCI), bioengineering initiatives, and the University-wide department of systems biology. Workers have been waterproofing the exterior cement walls and erecting the below-grade portions of the structural steel beams and columns for the first of four buildings planned for the site.

Yet a carefully worded University statement in January said that an “assessment of the project and the environment in which it is being developed” continues, a reference to the unfolding financial crisis (see "The Fiscal Crunch"). Emphasizing that “scientific excellence is first and foremost about people and programs,” University spokesperson Lauren Marshall said that even though “changed financial realities have dictated thorough review” of all capital planning, Harvard’s “commitment to interdisciplinary science will be sustained….”

The University’s institutional master plan for Allston, originally expected by the end of 2008, has also been delayed at least in part by pecuniary considerations. Such plans must specify both near- and longer-term construction commitments, implying the need for predictable funding. Marshall emphasized that “Harvard’s long-term commitment to Allston hasn’t diminished....The master planning process continues. We are rigorously evaluating our options and consulting with key stakeholders….” The University, she says, “is carefully considering a range of capital planning scenarios, but no final decisions have been made.”

You might also like

Lawrence Summers

Previously undisclosed Epstein links to Harvard affiliates leads to a University review.

FAS Cuts Science Ph.D. Admissions By Half

Backing off plans for more drastic reductions, the division still faces a long-term deficit.

Harvard Divinity School Sets New Priorities

After two years of turmoil, Dean Marla Frederick describes a more pluralistic future for the institution’s culture and curriculum.

Most popular

What Trump Means for John Roberts’s Legacy

Executive power is on the docket at the Supreme Court.

The Life of a Harvard Spy

Richard Skeffington Welch’s illustrious—and clandestine—career in the CIA

This Harvard Scientist Is Changing the Future of Genetic Diseases

David Liu has pioneered breakthroughs in gene editing, creating new therapies that may lead to cures.

Explore More From Current Issue

Illustration of tiny doctors working inside a large nose against a turquoise background.

A Flu Vaccine That Actually Works

Next-gen vaccines delivered directly to the site of infection are far more effective than existing shots.

Students in purple jackets seated on chairs, facing away in a grassy area.

A New Prescription for Youth Mental Health

Kenyan entrepreneur Tom Osborn ’20 reimagines care for a global crisis.